Naveen Babbar, Ph.D.

Naveen Babbar is Senior Vice President, Translation Medicine. Before joining Prelude, Naveen was Vice President of Global Precision Medicine at Novartis Pharmaceuticals. Naveen’s experience covers a wide span of solid tumor oncology drug and device development including translational studies across early and late-stage development, diagnostic assay development, global registrations and commercial launches. Naveen has contributed to successful NDA submissions for Zykadia® (ALK inhibitor), Kisqali® (CDK4/6 inhibitor), Piqray® (PIK3CA inhibitor) and Tabrecta® (cMET inhibitor), and their associated companion diagnostic assays globally. Naveen received his M.Sc. in Biotechnology from Delhi, India, Ph.D. in Biochemistry and Molecular Biology from University of Arizona and completed his postdoctoral fellowship from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.